Provided by Tiger Fintech (Singapore) Pte. Ltd.

Ascendis Pharma A/S

158.52
-3.0000-1.86%
Volume:123.21K
Turnover:19.55M
Market Cap:9.57B
PE:-25.19
High:165.26
Open:161.78
Low:156.28
Close:161.52
Loading ...

Ascendis Pharma price target lowered to $192 from $203 at BofA

TIPRANKS
·
13 Feb

Ascendis Pharma Allocates $25 Million for Share Repurchases, Net Settlement of RSUs

MT Newswires Live
·
13 Feb

Ascendis Pharma a/S : Jefferies Raises Target Price to $223 From $194

THOMSON REUTERS
·
13 Feb

Ascendis Pharma A/S Reports Strong 2024 Financial Growth

TIPRANKS
·
13 Feb

Ascendis Pharma A/S reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
13 Feb

Ascendis Pharma A/S Announces Share Repurchase Program & Net Settlement Of Certain Rsus

Reuters
·
13 Feb

Stock Track | Ascendis Pharma Soars 6% After Hours on Q4 Beat, Buyback Plan

Stock Track
·
13 Feb

Ascendis Pharma announces share repurchase program, settlement of certain RSUs

TIPRANKS
·
13 Feb

Ascendis Pharma Q4 Loss Narrows, Revenue Rises -- Shares Up After Hours

MT Newswires Live
·
13 Feb

Stock Track | Ascendis Pharma Soars 5.87% After Beating Q4 Estimates on Strong Sales Growth

Stock Track
·
13 Feb

Ascendis Pharma Q4 2024 GAAP EPS €(0.64) Beats €(1.07) Estimate, Sales €173.916M Beat €111.178M Estimate

Benzinga
·
13 Feb

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
12 Feb

Ascendis Pharma Price Target Maintained With a $170.00/Share by Cantor Fitzgerald

Dow Jones
·
11 Feb

Ascendis Pharma A/S expected to post a loss of €1.08 a share - Earnings Preview

Reuters
·
11 Feb

Morgan Stanley Remains a Hold on Ascendis Pharma (ASND)

TIPRANKS
·
10 Feb

Ascendis Pharma a/S : Morgan Stanley Raises Target Price to $175 From $167

THOMSON REUTERS
·
04 Feb

Ascendis Pharma A/S expected to post a loss of €1.14 a share - Earnings Preview

Reuters
·
03 Feb

European Equities Traded in the US as American Depositary Receipts Decline in Friday Trading

MT Newswires Live
·
01 Feb

Exploring High Growth Tech Stocks In January 2025

Simply Wall St.
·
30 Jan

Ascendis Pharma Is Maintained at Overweight by JP Morgan

Dow Jones
·
29 Jan